Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults
NCT04057833Phase 1Active, not recruiting
- Sponsor
- Hospital for Special Surgery
- Start
- Nov 2019
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of E-CEL UVEC in rotator cuff tear, sponsored by Hospital for Special Surgery. Primary endpoint: Short-term safety at 11 days. Started Nov 2019; status: active, not recruiting.
02
Drugs
E-CEL UVEC
03
Conditions
rotator cuff tear
Beyond the preview
Go deeper on NCT04057833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04057833.